Ayanna Pressley Opens Up About Living With Alopecia and Hair Loss
The congresswoman from Massachusetts said that she was making peace with the condition in a video released on Thursday.
Conclusion: The overall prevalence of AA among a population of Saudi patients is 2.3%. AA prevalence is higher in pediatrics than adults. Common comorbid conditions include hypothyroidism, diabetes mellitus, and atopic diseases. PMID: 32231700 [PubMed]
Authors: Asfour L, Yiu ZZN, Warren RB Abstract Introduction: Skin conditions are common and highly varied in their etiology; therefore, a diverse array of therapeutics are utilized. Drug safety studies in dermatology can be challenging as there are over 3000 diagnoses to consider. As a result, dermatologists rely on data from multiple sources including clinical trials and real-world evidence.Areas covered: In this review, we cover the main sources of safety data available, their strengths and weaknesses and how dermatologists should utilize such data. We use real-world examples of the different types of adverse eve...
Here’s an excerpt from the Revised &Expanded Edition of Wheat Belly, page 184: I had a heck of a time persuading Gordon to drop the wheat. I met Gordon because he had coronary disease. Among the causes: abundant small LDL particles along with the usual accompaniments of low HDL, high triglycerides, and high blood sugar. I asked him to completely remove the wheat from his diet in order to reduce or eliminate the small LDL particles and thereby obtain better control over heart health. Problem: Gordon owned a bakery. Bread, rolls, and muffins were part of his everyday routine, three meals a day, seven days a week. I...
Abstract BACKGROUND: Frontal Fibrosing Alopecia (FFA) is a scarring alopecia with unclear pathogenesis and a progressive course. The disease has a major impact on patients' quality of life, lacking effective treatments to halt disease progression. METHODS: We profiled lesional and non-lesional scalp biopsies collected in 2017 from FFA patients (n=12) in comparison to scalp biopsies from alopecia areata (AA) (n=8) and control (n=8) individuals to evaluate gene and protein expression including the primary outcome (CXCL9). We determined significant differences between biomarkers by a two-sided Student's t-test a...
Recognition reinforces baricitinib's potential to be the first FDA-approved medicine for individuals living with alopecia areata INDIANAPOLIS, March 16, 2020 -- (Healthcare Sales &Marketing Network) -- Eli Lilly and Company (NYSE: LLY) and Incyte Corp... Biopharmaceuticals, FDA Eli Lilly, baricitinib, alopecia areata
This article summarizes the milestones in the development of delgocitinib leading to this first approval for the treatment of adults with atopic dermatitis. Clinical development of the topical formulation is also underway for alopecia areata, chronic hand eczema, discoid lupus erythematosus, inverse psoriasis and atopic dermatitis in several countries worldwide. Clinical development of an oral formulation of delgocitinib is also underway in Japan for the treatment of autoimmune disorders and hypersensitivity.
CONCLUSIONS: The Scalp Hair Assessment PRO™ is a content-valid, clinically meaningful assessment of distinct gradations of scalp hair loss for evaluating AA treatment for patients with ≥50% hair loss at baseline. PMID: 32163589 [PubMed - as supplied by publisher]
A systematic review failed to identify any systemic therapy used in alopecia areata (AA) where use is supported by robust evidence from high quality randomized controlled trials (RCTs).
Condition: Alopecia Areata Interventions: Drug: Crisaborole Topical Ointment; Drug: Placebo Topical Ointment Sponsors: Tufts Medical Center; Pfizer Recruiting